BB Biotech's Reinvested Takeover Proceeds Face Their First Real Test
Published on 11/11/2026 at 03:54 | Editorial boerse-global.de
BB Biotech has already put its takeover windfall back to work. What the Swiss biotech investor cannot yet show is whether that redeployed capital will deliver. Christian Koch, who heads the BB Biotech team at Bellevue Asset Management, confirmed on 4 November that proceeds from the sales of Crinetics Pharmaceuticals and Nuvalent — roughly CHF 280 million — were reinvested during the same quarter, leaving the portfolio's next clinical and regulatory milestones as the yardstick by which the move will be judged.
The transactions sit within a broader reshaping. Koch said the company established twelve new positions and exited eight holdings, a rotation that makes the newcomers central to how the portfolio is valued from here. Five takeovers of portfolio companies were completed in 2026, according to company figures, and the Crinetics and Nuvalent deals supplied the cash that BB Biotech promptly redeployed.
Nine-month profit jumps, but the third quarter loses momentum
Those portfolio moves played out against sharply improved headline earnings. For the first nine months of 2026, BB Biotech reported a net profit of CHF 605 million, well ahead of the CHF 106 million booked in the same period a year earlier. The third quarter alone told a different story: net profit fell to CHF 175 million from CHF 448 million in the prior-year quarter.
Management pointed to strong contributions from individual index constituents outside its own therapeutic focus to explain the weaker relative performance against the Nasdaq Biotechnology Index. Rising interest rates in September also weighed on smaller biotech names, the company said.
Should investors sell immediately? Or is it worth buying BB Biotech?
The figures and portfolio changes trace back to the quarterly report published on 23 October. Koch had already flagged clinical progress at portfolio companies, completed takeovers and new investments in a commentary dated 30 October, and Bellevue representatives returned to those themes in a further comment released on 2 November.
A rally, then profit-taking
The share price has travelled a long way in a short time. Over 30 days the stock gained 10%, and a media report on 4 November attributed the most recent rebound to a countermove following profit-taking after that strong run. The same report identified the rising 200-day moving average as chart support.
Sector sentiment has also been shaped by names outside the BB Biotech portfolio, including Moderna and genomics specialists, according to that report. On the latest trading day the stock slipped 0.3% to close at EUR 57.90.
What investors must weigh
The bull case rests on the pattern already visible: holdings advance, takeovers crystallise gains, and the released capital opens fresh development opportunities. Should the upcoming milestones confirm expectations, the argument for the renewed portfolio would gain strength — with the completed deals serving as a starting point rather than the proof itself.
BB Biotech at a turning point? This analysis reveals what investors need to know now.
The bear case centres on the gap between successful capital release and the unproven record of the reinvestments. Disappointing clinical or regulatory results would undercut the favourable reading and force investors to reweight what has already been banked against what remains in development. The technical support only matters if it holds while the holdings approach their next tests; weak progress would raise the odds that profit-taking again drives the share price.
The next scheduled date on the corporate calendar is the Deutsches Eigenkapitalforum in Frankfurt on 24 November, giving investors an anchor for following the company's communication. The substance, though, lies in the announced clinical and regulatory milestones — the point at which a completed reinvestment either becomes a durable foundation or something less.
Ad
BB Biotech Stock: New Analysis - 11 November
Fresh BB Biotech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
